EP300 and Hyperglycemia: To reduce the epigenetic-driven senescence/calcification in human VICs, we treated sVICs with Pentadecylidenemalonate-1b (SPV106), a drug known to inhibit KAT3B/p300 and to activate KAT2B/pCAF histone acetylases18 already validated for reversion of hyperglycaemia-induced senescence in cardiac stromal cells.19 SPV106 reduced the sVICs calcification level, inhibited senescence markers, restored (at least in part) cell growth, and reverted the histone acetylation setup similar to that observed in iVICs.